• Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist that stimulates insulin release from the pancreas. Glucagon-like peptide -1 is a natural hormone that helps your body regulate your blood glucose.

• Semaglutide was first approved by the FDA for weight loss under the name of Wegovy in June of 2014.

• By increasing insulin production, Semaglutide helps your body burn calories.

• Semaglutide slows down the speed at which food travels through your digestive system (your stomach empties more slowly), causing you to eat less.

• Semaglutide acts on your brain’s hunger signal causing you to feel full, resulting in weight loss.

• Clinical studies have shown that Semaglutide can help to produce significant weight loss in overweight and obese individuals. Controlled trials showed that participants who took Semaglutide lost an average of 15% to 20 % of their body weight over 68 weeks, compared to an average of 2.4% weight loss in those who received a placebo.

• Semaglutide is administered as a subcutaneous injection once a week.

• It is started at a low dose to minimize side effects.

• Doses adjustments are considered every 4 weeks as needed.

• Semaglutide is recommended for adults who have a body mass index (BMI) of 30 kg/m² or greater, or for those with a BMI of 27 kg/m² or greater and at least one weight-related health condition such as high blood pressure, Type II diabetes, or high cholesterol.

• Semaglutide is also recommended for those who have tried to lose weight through diet and exercise but have been unsuccessful.

• Note: Individuals who have a history of pancreatitis or thyroid cancer should not use Semaglutide.

• It is important to talk to your healthcare provider to determine if Semaglutide is a good option for you.

To begin your Semaglutide weight loss journey all you need is to schedule your first Consultation Appointment by clicking the “Schedule your First Consultation” button at the bottom of this page.

Yes! If you are already receiving Semaglutide or Tirzepatide injections and would like to easily convert to our program, all you need is to schedule your first Consultation Appointment by clicking the “Schedule your First Consultation” button at the bottom of this page.

• Most patients who take Semaglutide find that they do not need additional weight management medications.

• However, Semaglutide should not be used in combination with other GLP-1 receptor agonists or medications that increase GLP-1 receptor activity. It may be used in combination with other weight loss medications, but the safety and efficacy of such combinations have not been studied.

• Any medications you are taking or wish to take at the same time as Semaglutide should be discussed with a qualified physician.

• Because Semaglutide mimics the body’s natural substances, replicating a hormone that the body produces naturally, it is generally well-tolerated and considered quite safe when prescribed by a qualified physician.

• The most common side effects of Semaglutide for weight loss include nausea, heartburn, vomiting, and constipation.

• Less common side effects include abdominal pain, pancreatitis, gallbladder stones or inflammation, acute kidney injury, low blood glucose, electrolyte imbalance, diabetic retinopathy, headache, fatigue and suicidal ideation.

These side effects typically subside over time, as the patient’s body gets used to the medication and they learn the routine of the new reduced fat and caloric intake.

• Most people will start seeing a decrease in their appetite, the sensation of being fuller faster and a decrease in their food intake in their first week. However, the entry dose is to allow your body to adjust to the new medication and to limit potential side effects. The entry dose is not considered an effective dose for significant weight loss.

• Expect to see better results after starting the higher doses. It usually takes about 8-12 weeks to titrate to the higher doses if you do not develop significant side effects.

• Weight loss results will vary from person to person, but clinical studies have shown that Semaglutide can help to produce significant weight loss in overweight and obese individuals.

• In clinical trials for Ozempic, participants lost an average of 13.5 pounds over 26 weeks when used in combination with moderate diet and exercise.

• In a 68-week study, participants taking Ozempic lost up to 20% of their body weight and those on Wegovy lost an average of 16.0% of their initial body weight, compared to 5.7% for those taking a placebo.

• Weight loss results are significantly better when combining Semaglutide with proper diet and exercise.